Class II alloantibody and mortality in simultaneous liver-kidney transplantation

American Journal of Transplantation

Volumn 13, Issue 4, 2013, Pages 954-960

  O'Leary, J G ^a   Gebel, H M ^b   Ruiz, R ^a   Bray, R A ^b   Marr, J D ^a   Zhou, X J ^a   Shiller, S M ^a   Susskind, B M ^a   Kirk, A D ^b   Klintmalm, G B ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody mediated rejection; donor specific antibodies; graft outcomes; liver transplant; renal transplant; simultaneous liver kidney transplant

Indexed keywords

ALLOANTIBODY; CYCLOSPORIN; STEROID; TACROLIMUS;

ADULT; ALLOGRAFT; ARTICLE; BLOOD ANALYSIS; DEATH; FEMALE; GRAFT SURVIVAL; HLA SYSTEM; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SIMULTANEOUS LIVER KIDNEY TRANSPLANTATION;

ADULT; BIOPSY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGISTRIES; RENAL INSUFFICIENCY; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84875727347     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12147     Document Type: Article

References (14)

1. Dar W, Agarwal A, Watkins C, et al. Donor-directed MHC class I antibody is preferentially cleared from sensitized recipients of combined liver/kidney transplants. Am J Transplant 2011; 11: 841-847.
2. Askar M, Schold JD, Eghtesad B, et al. Combined liver-kidney transplants: Allosensitization and recipient outcomes. Transplantation 2011; 91: 1286-1292.
3. Takaya S, Duquesnoy R, Iwaki Y, et al. Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. Transplant Proc 1991; 23 (Pt 1): 396-399.
4. Ogura K, Koyama H, Takemoto S, Terasaki PI, Busuttil RW,. Significance of a positive crossmatch on outcome in human liver transplantation. Transplant Proc 1992; 24: 1465.
5. Castillo-Rama M, Castro MJ, Bernardo I, et al. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: Role of human leukocyte antigen compatibility. Liver Transpl 2008; 14: 554-562. (Pubitemid 351524413)
6. Olausson M, Mjornstedt L, Norden G, et al. Successful combined partial auxiliary liver and kidney transplantation in highly sensitized cross-match positive recipients. Am J Transplant 2007; 7: 130-136. (Pubitemid 44952865)
7. Pei R, Wang G, Tarsitani C, et al. Simultaneous HLA Class I and Class II antibodies screening with flow cytometry. Hum Immunol 1998; 59: 313-322. (Pubitemid 28225990)
8. Bradley JA, Baldwin WM, Bingaman A, et al. Antibody-mediated rejection-an ounce of prevention is worth a pound of cure. Am J Transplant 2011; 11: 1131-1139.
9. O'Leary JG, Kaneku H, Suskind BM, Jennings LW, Terasaki PI, GB K,. high MFI preformed class I & de novo class II DSA accelerate fibrosis progression after liver transplant in HCV-infected patients. Am J Transplant 2011; Abstract 782.
10. O'Leary JG, Kaneku H, Susskind BM, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. Am J Transplant 2011; 11: 1868-1876.
11. Musat AI, Agni RM, Wai PY, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11: 500-510.
12. Hirohashi T, Chase CM, Della Pelle P, et al. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant 2012; 12: 313-321.
13. Kaneku H, O'Leary JG, Taniguchi M, Susskind BM, Terasaki PI, Klintmalm GB,. Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl 2012; 18: 984-992.
14. Paterno F, Shiller M, Tillery G, et al. Bortezomib for acute antibody-mediated rejection in liver transplantation. Am J Transplant 2012; 12: 2526-2531.